<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932669</url>
  </required_header>
  <id_info>
    <org_study_id>1811-074-985</org_study_id>
    <nct_id>NCT03932669</nct_id>
  </id_info>
  <brief_title>Effect of Nilotinib in Cerebellar Ataxia Patients</brief_title>
  <official_title>Effect of Nilotinib in Cerebellar Ataxia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an institutional cohort study. Patients confirmed with spinocerebellar ataxia (SCA)&#xD;
      and taking or planning to take Nilotinib (TasignaÂ®) are enrolled in this study. The daily&#xD;
      dose of Nilotinib is 150mg-300mg and the patients will be followed up at 1, 3, 6, and 12&#xD;
      months. Rating scale for Friedreich's ataxia I and II and Barthel index are used as general&#xD;
      function and daily living performance index. Scale for assessment and rating of ataxia (SARA)&#xD;
      are used as an objective measure of cerebellar function. Adverse drug reactions are evaluated&#xD;
      based on CTCAE version 4.0.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Patients taking Nilotinib 1-1.Baseline information: demographics, genetic type of SCA,&#xD;
           brain MRI, electrocardiography, routine blood evaluations 1-2. Time point of evaluation:&#xD;
           At initiation of taking Nilotinib, 1, 3, 6, and 12 months 1-3. Evaluation items (at each&#xD;
           time point) Routine check-up: electrocardiography, routine blood evaluations Adverse&#xD;
           events: CTCAE version 4.0 Daily living performance: Barthel index General function:&#xD;
           Friedreich's ataxia I and II 1-4. Change of drug dose Based on the attending physician's&#xD;
           decision&#xD;
&#xD;
        2. Patients planning to take Nilotinib 2-1.Baseline information: demographics, genetic type&#xD;
           of SCA, brain MRI, electrocardiography, routine blood evaluations 2-2. Time point of&#xD;
           evaluation: Baseline, 1, 3, 6, and 12 months 2-3. Evaluation items (at each time point)&#xD;
           Routine check-up: electrocardiography, routine blood evaluations Adverse events: CTCAE&#xD;
           version 4.0 Cerebellar function: Scale for assessment and rating of ataxia (SARA) Daily&#xD;
           living performance: Barthel index General function: Friedreich's ataxia I and II 2-4.&#xD;
           Change of drug dose Based on the attending physician's decision&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Actual">August 13, 2020</completion_date>
  <primary_completion_date type="Actual">August 13, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activity of daily living</measure>
    <time_frame>12 month</time_frame>
    <description>Barthel index: score range 0-6</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cerebellar function</measure>
    <time_frame>12 month</time_frame>
    <description>Scale for the assessment and rating of ataxia (SARA): score range 0-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General function</measure>
    <time_frame>12 month</time_frame>
    <description>Rating scale for Friedreich's ataxia I: score range 0-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity of daily living</measure>
    <time_frame>12 month</time_frame>
    <description>Rating scale for Friedreich's ataxia II: score range 0-36</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Baseline, 1 month, 3 month, 6 month, 12 month</time_frame>
    <description>CTCAE version 4.0</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Ataxia, Cerebellar</condition>
  <condition>Ataxia, Progressive</condition>
  <arm_group>
    <arm_group_label>Nilotinib group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with SCA and taking nilotinib treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>150-300mg daily dose of nilotinib</description>
    <arm_group_label>Nilotinib group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed as chronic cerebellar ataxia&#xD;
&#xD;
          -  Confirmed as spinocerebellar ataxia by gene test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Laboratory abnormalities that could interfere with the proper use of Nilotinib QTc&#xD;
             interval &gt;450ms on initial electrocardiograph, Hb &lt;8.0, WBC&lt;2000, ANC &lt;1600, PLT&#xD;
             &lt;140,000, AST &gt;200, ALT&gt;200, ALP&gt;575, Positive HIV serology, active hepatitis B&#xD;
&#xD;
          -  Unstable mental or physical status that could interfere with precise evaluation and&#xD;
             proper management of SCA Heart failure (NYHA Grade III or IV), history of major heart&#xD;
             disease Pregnancy, on breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kon Chu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Lee WJ, Moon J, Kim TJ, Jun JS, Lee HS, Ryu YJ, Lee ST, Jung KH, Park KI, Jung KY, Kim M, Lee SK, Chu K. The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia. J Neuroimmunol. 2017 Aug 15;309:82-87. doi: 10.1016/j.jneuroim.2017.05.015. Epub 2017 May 24.</citation>
    <PMID>28601294</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kon Chu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>spinocerebellar ataxia</keyword>
  <keyword>treatment</keyword>
  <keyword>nilotinib</keyword>
  <keyword>bcr-abl</keyword>
  <keyword>receptor-tyrosine-kinase-inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The IPD will be provided upon request from any qualified investigator.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

